Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 8/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CASP2 | P42575 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26178758 | 0.84 | TDP1 (0.73) | TDP1EPHX1MAOAMAOBCA12 | |
| SCHEMBL3365771 | 0.84 | TDP1 (0.73) | TDP1EPHX1MAOAMAOBCA12 | |
| SCHEMBL28923405 | 0.84 | TDP1 (0.73) | TDP1EPHX1MAOAMAOBCA12 | |
| SCHEMBL14877952 | 0.84 | TDP1 (0.73) | TDP1EPHX1MAOAMAOBCA12 | |
| SCHEMBL16436993 | 0.84 | TDP1 (0.73) | TDP1EPHX1MAOAMAOBCA12 | |
| SCHEMBL25319217 | 0.84 | TDP1 (0.73) | TDP1EPHX1MAOAMAOBCA12 | |
| SCHEMBL7106115 | 0.84 | TDP1 (0.73) | TDP1EPHX1MAOAMAOBCA12 | |
| SCHEMBL8737682 | 0.84 | TDP1 (0.73) | TDP1EPHX1MAOAMAOBCA12 | |
| SCHEMBL4553865 | 0.84 | TDP1 (0.73) | TDP1EPHX1MAOAMAOBCA12 | |
| SCHEMBL4721611 | 0.84 | TDP1 (0.73) | TDP1EPHX1MAOAMAOBCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180311342-A1 | IMMUNOSTIMULATING AGENT | AJINOMOTO CO., INC. (JP) | 2018-11-01 | — | — | US | disclosed |
| EP-3395365-A1 | IMMUNOSTIMULATING AGENT | AJINOMOTO CO., INC. (JP) | 2018-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180311342-A1 | IMMUNOSTIMULATING AGENT | MYD88, TLR9, IL2 | TDP1 4542/4885EPHX1 2378/4885MAOA 4024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.